ANDA 75509, held by Aurobindo Pharma USA. Doxazosin Mesylate.
As of Nov 16, 2026, ANDA 75509 (Doxazosin Mesylate), held by Aurobindo Pharma USA, was first approved by FDA on Oct 19, 2000, with 8 approved supplements and 0 published complete response letters.
Doxazosin tablets are an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 19, 2000 | Original application | Approved |
| Doxazosin MesylateEQ 1MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
| Doxazosin MesylateEQ 2MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
| Doxazosin MesylateEQ 4MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
| Doxazosin MesylateEQ 8MG BASE · tablet;oral | Doxazosin Mesylate | Rx |
| Aug 3, 2026 | Supplement 21Labeling · Standard review | Approved | None posted |
| Feb 21, 2017 | Supplement 18Labeling · Standard review | Approved | None posted |
| Feb 24, 2015 | Supplement 16Manufacturing | Approved | None posted |
| Sep 22, 2014 | Supplement 17Labeling · Standard review | Approved | None posted |
| Jul 8, 2011 | Supplement 15Labeling | Approved | None posted |
| Oct 1, 2007 | Supplement 8Labeling | Approved | None posted |
| Jan 21, 2004 | Supplement 3Labeling | Approved | None posted |
| Mar 25, 2002 | Supplement 1Labeling | Approved | None posted |
| Oct 19, 2000 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters